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Optic neuritis (On) is the presence of an acute 
inflammation of the optic nerve that results in painful loss of 
vision. it is the most commonly encountered optic neuropathy 
in general practice,1–4 and is often associated with multiple 
sclerosis (ms).3,4 studies show that in about 15–20% of ms 
cases, On was the presenting symptom and more than half of 
people with ms experience at least one episode of On during 
their disease.5,6 the risk of developing ms can be stratified by 
appropriate imaging investigations at the diagnosis of On. 
therefore, early recognition is important to ensure timely 
referral, investigation and treatment; prompt treatment can 
hasten visual recovery.
epidemiology
Annually, the incidence and prevalence of ON in the United States of 
America is five per 100 000 and 115 per 100 000 respectively.7 There 
are no published Australian data. Caucasians, females and people living 
in higher latitudes are more likely to be affected.8–11 It commonly occurs 
between the ages of 15–49 years (mean age 30–35 years3). 
 In children, ON has a mean onset of 9–12 years;3,12 commonly 
coincides with the peak incidence of viral infection;3 and has equal 
gender distribution.3
aetiology
Optic neuritis may be due to demyelination (associated with 
MS),2,3 infection, parainfection or autoimmune disease. In adults, 
demylinating causes are common, and idiopathic demyelinating ON is 
the commonest cause.
 In adults, infectious causes are rare but include herpes 
zoster, Lyme disease, syphilis, tuberculosis, cat scratch disease, 
toxoplasmosis, toxocariasis, cytomegalovirus and fungi, adenovirus, 
measles, mumps or chicken pox.2,3 Parainfectious causes from 
sinus disease, vaccination and encephalitis have been reported.1–3 
Autoimmune ON has been reported in systemic lupus erythematosus, 
Sjogren syndrome, ankylosing spondylitis, diabetes mellitus, temporal 
arteritis, and sarcoidosis.1–3 
Background
Optic neuritis is an acute inflammation of the optic nerve that 
results in painful loss of vision. Patients often present to a general 
practitioner, and early recognition is important as treatment may 
improve the speed of vision recovery. 
Objective
This article provides information on the signs and symptoms of optic 
neuritis and discusses appropriate referral, investigations  
and management. 
Discussion 
Optic neuritis is the presenting symptom in up to one-fifth of people 
with multiple sclerosis. Diagnosis of optic neuritis is based on 
history and examination, therefore obtaining pertinent information 
and performing proper ophthalmic examination is essential. Prompt 
recognition and appropriate referral is important to facilitate 
investigations such as magnetic resonance imaging of the brain that 
can help predict risk in the development of multiple sclerosis. 
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or ‘boring’. A salient feature is increased pain with extraocular 
movement.11 Ocular pain can either precede or simultaneously occur 
with subacute unilateral visual loss, which can progress over several 
hours to days, peaking within 10 days.1–3 
 Proper ophthalmic examination is essential to determine whether 
a patient has ON. Clinical signs of optic nerve dysfunction are:
•	decreased	visual	acuity	(VA)
•	decreased	colour	vision
•	presence	of	relative	afferent	pupillary	defect	(RAPD)
•	reduction	in	subjective	brightness
•	visual	field	defect
•	abnormal	contrast	sensitivity,	and	
•	certain	 appearances	 of	 the	 optic	 nerve	 (swelling,	 peripapillary	
haemorrhage or pallor).
Visual acuity and colour vision
In general practice, the signs of optic nerve dysfunction can be 
elicited	 from	 testing	 the	 VA	 using	 a	 Snellen	 chart,	 or	 an	 age	
dependent chart for children, to determine the degree of vision 
loss.1,3	 Visual	 acuity	 in	 ON	 can	 range	 from	 6/6	 to	 no	 perception	
of light. Examination of colour vision is imperative and this can 
be detected with the use of a pseudo-isochromatic plates such as 
Ishihara plates (Figure 2). The most common pattern in ON is red-
green confusion.13 
 Relative afferent pupillary defect is the most important objective 
sign of unilateral ON and it is vital that this test is performed correctly 
(see the article ‘Sudden loss of vision‘ in this issue). If a RAPD is not 
demonstrated, possibilities include bilateral simultaneous optic ON or 
previous contralateral eye ON.14,15 
 The Optic Neuritis Treatment Trial (ONTT) showed approximately 
48% of patients with ON in one eye had evidence of optic 
neuropathy in the contralateral eye.16 In children, ON is quite often 
bilateral and simultaneous.
 Subjective decrease in brightness is another indicator of optic 
nerve dysfunction. This can be performed by shining a light source in 
each eye separately, and then asking the patient if the light appears 
equally bright. The light will appear less bright in the affected eye. 
Field defects
In the general practice setting, visual field defect can be elicited 
with a red pin to compare blind spots between the examiner and the 
patient. Diffuse visual field defects may not be elicited using direct 
confrontation and may only be detected by ophthalmologist directed 
automated perimetry (Figure 3). 
Fundoscopy
Anterior ON involves the optic nerve head and occurs in about 
35% of patients. With the use of a direct ophthalmoscope, optic 
nerve swelling or papillitis can be seen (Figure 4).8,11 Sometimes, 
peripapillary haemorrhage or retinal exudate are also seen. The 
presence of papillitis, peripapillary haemorrhage and retinal exudate 
 In children, ON is commonly caused by infection such as 
adenovirus, measles, mumps and chickenpox, followed by 
parainfectious causes postvaccination.3
pathology
Inflammation of the optic nerve and it’s lining results in inflammation 
of the extraocular recti muscles that surround the optic nerve. Recti 
muscle involvement results in ocular pain, especially with eye 
movements. Regardless of aetiology, inflammatory cells surround 
the optic nerve2 resulting in swelling and fragmentation of the 
nerve tissue.2 Subsequently, these fragments are phagocytised by 
macrophages resulting in further degeneration of the nerve and the 
signs of optic nerve dysfunction.2 
clinical features
History and examination are the basis of diagnosis.2–4 Adult patients 
with ON often notice a unilateral decrease in vision.2–4 Bilateral 
involvement can occur, but this is more common in children or in 
Asian populations and is referred to as ‘optospinal MS’.3,4,9 Colour 
vision is usually affected, with colours appearing ‘washed out’ (Figure 
1) before any decline of vision occurs.4,11 There is often orbital pain 
in or around the eye,11 which is typically described as ‘dull’, ‘achy’, 
Figure 1. Normal colour vision (left). Red desaturation during an 
episode of ON (right) (red objects appear washed out)
Figure 2. A sample of an Ishihara 
pseudoisochromatic plate. The colour vision 
testing should be performed in good lighting 
and monocularly by covering one eye at a time. 
The eye with ON usually shows colour deficit 
resulting in abnormal response (eg. reporting a 
number 3 when it is a number 8 on the plate) or 
not being able to see the number on the plate
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to help predict the risk of developing clinically definite MS.17,18 
The cumulative probability of developing MS by 15 years after the 
onset	 of	ON	 is	 50%	 (95%	 confidence	 interval,	 44–56%).	 This	 risk	
increased to 72% in patients with one or more lesions on MRI.17 The 
characteristic demyelinating lesions are 3 mm or more in diameter, 
ovoid, located in periventricular areas of the white matter, and radiate 
toward the ventricular spaces (Figure 6).4 Retrobulbar ON is best seen 
on a T1 weighted gadolinium enhanced MRI of the orbit, seen as a 
hyperintense signal of the optic nerve. 
 Diagnostic criteria of MS were updated in 2001 with the 
McDonald criteria taking into account the advances in MRI imaging.21 
The McDonald criteria classifies a person as having MS when there 
are clinical features of two or more attacks and two or more objective 
clinical lesions on MRI. 
 In children, the relationship between MRI lesions and MS is 
less definite. However, recent studies have demonstrated that the 
presence of one or more white matter lesions on baseline MRI brain 
increases the risk of MS.12,22
lumbar puncture
Lumbar puncture is now used less commonly and is controversial,1 
but cerebrospinal fluid (CSF) examination is useful in patients with 
with a normal MRI brain decrease the risk of developing MS.17,18 
 Retrobulbar ON, where the inflammation occurs behind the 
optic nerve head, is more typical of idiopathic demyelinating 
disease and occurs in two-thirds of cases.8,11 In retrobulbar ON, 
the optic nerve looks normal but may develop pallor after 8 weeks 
from the onset of ON (Figure 5). A young female with vision loss, 
pain with eye movements and a normal looking optic nerve is likely 
to have retrobulbar ON.
racial variants
There are racial variants in ON presentation that are important 
to note. A Singapore study demonstrated that ocular pain is less 
common in Asians compared to caucasians, while papillitis and disc 
haemorrhages are more common in Asians.19 Furthermore, African 
Americans	were	 noted	 to	 have	 significant	 decreased	 VA	 at	 onset	
and after 1 year following a single initial episode of ON compared to 
caucasians within the same study group.20 
children
The presentation of ON in children is different to that seen in 
adults. Bilateral disease (simultaneous or sequential)3,9 is more 
common and visual loss is often profound. A history of viral 
illness 2 weeks before ocular features and recent vaccination is 
important.3,13 The most common visual field deficit in children is 
central scotoma.3,13 Other visual field defects include generalised 
constriction and altitudinal defects.3,13 
investigations
The diagnosis of ON is largely based on clinical features – investigation 
confirms the diagnosis and helps determine pathogenesis. 
Brain mri
A noncontrast MRI is the most important baseline investigation 
Figure 3. Automated perimetry grey scale showing a) a normal right 
visual field at baseline. The right blind spot’s inferior and temporal 
boarders are noted by the black arrows; b) the right visual field of 
the same person during acute episode of ON showing an inferior 
arcuate scotoma (area seen as black areas in the grey scale). The 
blind spot (original inferior margin denoted by a white arrowhead) 
has enlarged inferiorly and nasally
Figure 5. a) In retrobulbar ON the appearance of the optic nerve 
is normal at onset; b) Optic nerve pallor (arrows) is usually seen 8 
weeks after the episode of retrobulbar ON with the neuroretinal rim 
losing the orange appearance and appearing pale
Figure 4. Papillitis with peripapillary haemorrhage (arrows) surrounding 
the optic nerve of the right eye during an acute episode of ON
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followed by a tapering oral steroid course.11 Oral steroids alone 
are not recommended as studies have shown it resulted in a higher 
recurrence of ON in the same or fellow eye at the 10 year mark.10,11 
 In autoimmune causes of ON, steroids are the mainstay of 
treatment. If infectious causes are suspected, steroids should be 
withheld until appropriate antimicrobial agents are instituted.
 There are no set guidelines for treatment of ON in children. Several 
studies recommended the use of intravenous methylprednisolone 
(10–30	mg/kg/day	for	3–5	days)	to	treat	vision	loss.3,13,22
 Several large, randomised controlled trials demonstrate that 
an immunomodulator reduces the development of MS after 
ON.4,26–29 In Australia, the approved use of immunomodulators is 
restricted to ambulatory patients with specifically defined relapsing-
remitting MS.29 However, immunomodulators may be available on 
compassionate grounds in selected patients and referral of these 
patients to a neurologist or neuro-ophthalmologist for consultation 
and management is warranted. 
summary of important points
•	Demyelinating	optic	neuritis	may	be	related	to	MS.	
•	Diagnosis	is	largely	based	on	history	and	physical	examination.	
•	Patients	 often	present	with	 vision	 loss	 and	discomfort	 around	 the	
eye that is aggravated by eye movement. 
•	Clinical	 signs	 include	 decreased	 visual	 acuity,	 decreased	 colour	
vision, presence of RAPD, decreased subjective brightness and 
visual field abnormality. Appearance of the optic nerve head can 
either be swollen (papillitis) or normal. 
•	The	 characteristic	white	matter	 lesion	 on	MRI	 brain	 is	 the	most	
important predictor in the development of MS. 
•	Early	 recognition	 of	 ON	 is	 essential	 for	 prompt	 referral	 to	 an	
ophthalmologist. 
•	Treatment	 for	 the	 acute	 episode	of	ON	with	 IV	methylprednisone	
followed by oral prednisolone hastens the rate of vision recovery. 
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